# Edwards Lifesciences

> Edwards Lifesciences develops and manufactures implantable heart valves, catheter-based valve repair and replacement systems, and surgical heart technologies. Its customers are hospitals and cardiac centers worldwide. Following its 2024 Critical Care divestiture, the company concentrates on structural heart disease.

- **Founded:** 1958
- **Headquarters:** Irvine, United States
- **Founders:** Miles Lowell Edwards (Founder; engineer)
- **Products:** SAPIEN transcatheter aortic valves, SAPIEN 3 Ultra RESILIA, PASCAL Precision, EVOQUE, SAPIEN M3
- **Notable:** Starr-Edwards became the first commercially available artificial heart valve., SAPIEN received initial FDA approval in 2011., EVOQUE received FDA approval on February 1, 2024.

## Products & services

- **SAPIEN transcatheter aortic valves** — Balloon-expandable tissue valves and delivery systems for aortic valve replacement; the original SAPIEN received initial U.S. approval for inoperable patients in 2011.
- **SAPIEN 3 Ultra RESILIA** — Aortic transcatheter valve platform using Edwards’ RESILIA tissue technology.
- **PASCAL Precision** — Catheter-delivered leaflet repair for selected patients with degenerative mitral regurgitation; initial FDA approval September 2022.
- **EVOQUE** — Catheter-delivered tricuspid valve replacement; initial FDA approval February 2024.
- **SAPIEN M3** — Transseptal mitral valve replacement for eligible patients unsuitable for surgery or edge-to-edge repair; FDA approval December 22, 2025.
- **INSPIRIS RESILIA, MITRIS RESILIA and KONECT RESILIA** — Surgical aortic valve, mitral valve and aortic valved conduit platforms using RESILIA tissue.

## Achievements

- Starr-Edwards became the first commercially available artificial heart valve.
- SAPIEN received initial FDA approval in 2011.
- EVOQUE received FDA approval on February 1, 2024.
- SAPIEN M3 received FDA approval on December 22, 2025.

## Latest updates

- **2026-07** — Second-quarter sales reached $1.74 billion; Edwards raised full-year constant-currency sales growth guidance to 10%-11%.
- **2026-02** — Reported 2025 net sales of $6.0676 billion, up 11.5% on a reported basis.
- **2026-01** — Abandoned the JenaValve acquisition following a federal court injunction.
- **2025-12** — FDA approved SAPIEN M3 transcatheter mitral valve replacement.

## Links

- Website: https://www.edwards.com/
- LinkedIn: https://www.linkedin.com/company/edwards-lifesciences
- Twitter/X: https://twitter.com/edwardslifesci
- YouTube: https://www.youtube.com/user/EdwardsGlobal
- Instagram: https://www.instagram.com/edwardslifesciences/
- Facebook: https://www.facebook.com/Edwardslifesciences/

---

Profile page: https://yespress.io/edwards-lifesciences
Published by YesPress — https://yespress.io
Last updated: 2026-10-22